Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Henry Ji, Ph.D. Chief Executive Officer, President & Chairperson 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Na ...

Core Insights - Datavault AI has successfully closed the second tranche of equity financing with Scilex Holding Company, involving the issuance of a pre-funded warrant for approximately 263.91 million shares in exchange for about 1,237.6 Bitcoin [1][8] - The strategic investment aims to enhance Datavault's digital asset reserves, accelerate supercomputing infrastructure, support platform expansion, and create new revenue streams [2] - Datavault has granted Scilex an exclusive worldwide license for its AI-driven technology tailored for the biotech and biopharma industry, enabling the creation of a Biotech Exchange platform [3] Financial Details - The second tranche follows an initial investment in September 2025, valued at approximately $8 million in Bitcoin [1] - Under the licensing agreement, Datavault will receive a nonrefundable upfront license fee of $2.5 million in four installments, totaling $10 million, and is eligible for sales milestone payments up to $2.55 billion [4] Leadership Commentary - Scilex CEO Henry Ji expressed confidence in the collaboration, highlighting the alignment of Datavault's technologies with the biotech sector's needs for advanced data analytics and supercomputing power [5] - Datavault CEO Nathanial Bradley welcomed Scilex as a major stockholder, emphasizing the shared vision for leveraging digital assets to capture market share in the biotech sector [5] Company Overview - Datavault AI specializes in AI-driven data experiences and asset monetization in the Web 3.0 environment, offering solutions across various industries including biotech, fintech, and healthcare [6][7] - The company’s technology suite includes customizable AI and Machine Learning automation, detailed analytics, and marketing automation [9]

Core Insights - Datavault AI Inc. has granted an exclusive worldwide license to Scilex Holding Company for its AI-driven technology, aimed at creating a Biotech Exchange platform for secure tokenization and monetization of biotech assets [1][2][3] - The agreement highlights the potential to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, providing an alternative for companies to secure non-dilutive funding [3][4] - Datavault AI's robust intellectual property portfolio includes key patents that support the secure tokenization and exchange of sensitive genetic information [4][6] Licensing Agreement Details - Datavault AI will receive a non-refundable upfront license fee of $10 million, paid in four installments of $2.5 million each by Scilex [6][8] - Additionally, Datavault AI is eligible for sales milestone payments of up to $2.55 billion based on Scilex achieving certain sales milestones [7][8] Technology and Market Potential - The technology licensed to Scilex is expected to extend into a Pharmaceutical Exchange platform, potentially transforming the pharmaceutical industry [2] - The tokenization opportunity in the pharmaceutical sector is significant, with estimates suggesting a market size of $2.0 trillion for drug sales and diagnostics [3][4] Intellectual Property and Innovations - Datavault AI's intellectual property includes a pending patent for "Platform and Method for Tokenizing DNA Data," which establishes a secure framework for tokenizing genetic information [4][6] - The company has a comprehensive suite of issued and pending patents that support the Biotech Exchange, enabling secure data handling and monetization [4][6] Previous Collaborations and Technological Advancements - The licensing agreement builds on Datavault AI's previous collaborations, including work with Brookhaven National Laboratory on biofuel research [5] - Datavault AI's technology suite is customizable and includes AI and Machine Learning automation, third-party integration, and detailed analytics [9]

Core Viewpoint - Semnur Pharmaceuticals has successfully completed its business combination with Denali Capital Acquisition Corp, transitioning to a public company to enhance growth and address non-opioid pain management needs [1][2][3] Company Overview - Semnur Pharmaceuticals, Inc. is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies, particularly targeting moderate to severe chronic radicular pain/sciatica with its product candidate SP-102 (SEMDEXA™) [4][5] - The combined company will operate under the name Semnur Pharmaceuticals, Inc., with shares trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW" starting September 23, 2025 [2][7] Business Combination Details - The business combination was officially closed on September 22, 2025, allowing Semnur to access public capital markets for business growth [1][3] - Scilex Holding Company owns approximately 87.5% of Semnur's common stock post-business combination, indicating strong backing for the company's future endeavors [7] Leadership Statements - Henry Ji, Executive Chairperson of Semnur, emphasized the importance of public capital markets in enhancing business growth and fulfilling the company's mission [3] - Jaisim Shah, CEO of Semnur, expressed pride in the company's leadership in non-opioid therapeutics and the aim to accelerate access to these treatments through advancing clinical development and payer adoption [3] Product Development Focus - Semnur is advancing its second Phase 3 clinical development for SP-102, which is a novel gel formulation for epidural administration aimed at treating chronic radicular pain/sciatica [3][4] - The company is committed to increasing access to prescription non-opioid therapeutics and expanding its market presence [3]

Table of Contents (Exact name of Registrant as specified in its charter) Delaware 2836 92-1062542 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 As filed with the U.S. Securities and Exchange Commission on August 4, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on July 19, 2023 Registration No. 333-271401 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 92-1062542 (Primary Standard Industrial Classification Code Number) (I.R.S. Empl ...

As filed with the U.S. Securities and Exchange Commission on July 12, 2023 Registration No. 333-271401 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 92-1062542 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificatio ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on April 21, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Scilex Holding Company (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) ...